《Nature,1月29日,SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2021-02-22
  • SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus

    Mikail Dogan, Lina Kozhaya, Lindsey Placek, Courtney Gunter, Mesut Yigit, Rachel Hardy, Matthew Plassmeyer, Paige Coatney, Kimberleigh Lillard, Zaheer Bukhari, Michael Kleinberg, Chelsea Hayes, Moshe Arditi, Ellen Klapper, Noah Merin, Bruce Tsan-Tang Liang, Raavi Gupta, Oral Alpan & Derya Unutmaz

    Communications Biology volume 4, Article number: 129 (2021)

    Abstract

    Development of antibody protection during SARS-CoV-2 infection is a pressing question for public health and for vaccine development. We developed highly sensitive SARS-CoV-2-specific antibody and neutralization assays. SARS-CoV-2 Spike protein or Nucleocapsid protein specific IgG antibodies at titers more than 1:100,000 were detectable in all PCR+ subjects (n = 115) and were absent in the negative controls. Other isotype antibodies (IgA, IgG1-4) were also detected. SARS-CoV-2 neutralization was determined in COVID-19 and convalescent plasma at up to 10,000-fold dilution, using Spike protein pseudotyped lentiviruses, which were also blocked by neutralizing antibodies (NAbs). Hospitalized patients had up to 3000-fold higher antibody and neutralization titers compared to outpatients or convalescent plasma donors. Interestingly, some COVID-19 patients also possessed NAbs against SARS-CoV Spike protein pseudovirus. Together these results demonstrate the high specificity and sensitivity of our assays, which may impact understanding the quality or duration of the antibody response during COVID-19 and in determining the effectiveness of potential vaccines.

相关报告
  • 《1月29日_SARS-CoV-2特异性抗体和中和测定揭示了针对病毒的广泛体液免疫应答》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2021-02-23
    • 康涅狄格大学和纽约大学等机构的研究人员1月29日在期刊Communications Biology上在线发表了题为“SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus”的文章。 文章称,对感染SARS-CoV-2的患者实施抗体保护是公共卫生和疫苗开发的紧迫问题。研究人员开发了对SARS-CoV-2抗体高度敏感的特异性抗体中和测定。在所有PCR阳性的受试者(n=115)中均检出滴度超过1:100000的SARS-CoV-2刺突蛋白或核衣壳蛋白特异性IgG抗体,阴性对照组未检出。研究人员还检测出了其他同型抗体(IgA、IgG1-4)。利用SARS-CoV-2刺突蛋白假型慢病毒对COVID-19患者和康复患者血浆以10000倍的稀释度进行中和测定,结果显示病毒也被中和抗体(NAbs)阻断。住院患者的抗体和中和滴度比门诊患者或恢复期血浆供者高3000倍。有趣的是,一些COVID-19患者还拥有针对SARS-CoV刺突蛋白假型病毒的抗体。这些结果表明,该检测方法具有很高的特异性和敏感性,可以帮助研究人员检测针对SARS-CoV-2的抗体反应的质量,并影响确定潜在疫苗的有效性。 原文链接:https://www.nature.com/articles/s42003-021-01649-6
  • 《Nature,4月24日,Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-04-25
    • Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig Changhai Lei, Kewen Qian, Tian Li, Sheng Zhang, Wenyan Fu, Min Ding & Shi Hu Nature Communications volume 11, Article number: 2070 (2020) Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, at the end of 2019, and there are currently no specific antiviral treatments or vaccines available. SARS-CoV-2 has been shown to use the same cell entry receptor as SARS-CoV, angiotensin-converting enzyme 2 (ACE2). In this report, we generate a recombinant protein by connecting the extracellular domain of human ACE2 to the Fc region of the human immunoglobulin IgG1. A fusion protein containing an ACE2 mutant with low catalytic activity is also used in this study.